CN102697873A - Compound Chinese medicinal preparation for preventing and treating swine influenza viruses - Google Patents
Compound Chinese medicinal preparation for preventing and treating swine influenza viruses Download PDFInfo
- Publication number
- CN102697873A CN102697873A CN2012101862336A CN201210186233A CN102697873A CN 102697873 A CN102697873 A CN 102697873A CN 2012101862336 A CN2012101862336 A CN 2012101862336A CN 201210186233 A CN201210186233 A CN 201210186233A CN 102697873 A CN102697873 A CN 102697873A
- Authority
- CN
- China
- Prior art keywords
- swine influenza
- chinese medicine
- hole
- preventing
- chinese medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a compound Chinese medicinal preparation for preventing and treating swine influenza viruses. The preparation is characterized by consisting of 38 to 46 weight parts of honeysuckle, 34 to 42 weight parts of red peony root and 18 to 22 weight parts of male fern rhizome. Compared with the prior art, the invention has the advantages that the preparation is rich in medicament source, low in residual toxicity or residual toxicity prevention and low in side effect, avoids medicament resistance and can regulate the immunity of the body, inhibit virus replication and eliminate clinical symptoms.
Description
Technical field
The invention belongs to the field of Chinese medicines for animals, particularly suppress the swine influenza virus Chinese traditional compound medicine.
Background technology
Swine flue (swine influenza; SI) claim swine influenza again; Be swine influenza virus (swine influenza virus by the A of orthomyxovirus section type Influenza Virus; SIV) a kind of acute, hot, the height contact respiratory infectious disease that cause, clinical with burst, hyperpyrexia, cough, dyspnea, outbreak repeatedly, sickness rate is high, mortality rate is low is characteristic.This disease all has generation all over the world, harm is serious, and economic loss is huge, and human beings'health is constituted a threat to.Its outstanding epidemic characteristic is secondary or the mixed infection that often has and often cause other respiratory tract antibacterials and virus with subclinical form; Like pig breeding and breathing syndrome, pig circular ring virus 2 viral disease and porcine contagious pleuropneumonia etc.; Make epidemic situation become complicated, mortality rate increases.
In the control of clinical practice swine flue, the characteristics that have the control complication owing to antibiotic are widely used, and cooperate medicines such as a large amount of antipyretic-antalgics, glucocorticoids simultaneously.Yet when suppressing the body inflammatory reaction, also deepened immunosuppressant, caused the state of an illness more to worsen.
Summary of the invention
The purpose of this invention is to provide that a kind of medicine source is abundant, residual hazard is lower or do not have residual hazard, side effect little, be difficult for producing chemical sproof, can regulate body's immunity simultaneously, suppress virus replication, improve the herbal mixture of the control swine influenza virus of clinical symptoms
Medicament
The Chinese medicine compound that the purpose of this invention is to provide three kinds of effective anti-swine flu viruses.
The present invention is achieved in that by Flos Lonicerae 38-46 weight portions, Radix Paeoniae Rubra 34-42 weight portions, and Rhizoma Dryopteris Crassirhizomatis 18-22 weight portions constitute.
Owing to adopt pure Chinese medicine; Therefore; Residual hazard is lower or do not have residual hazard, side effect is little, difficult produces drug resistance, and each Chinese medicine ingredients all is to obtain medical material easily; Through in vitro tests and in vivo test, comprehensive study proves that all the present invention has the effect of control swine influenza virus on the mechanism of action and the clinical practice.
Here, for easy to use, the formation of 100g each component of the present invention is crushed at least 20 orders, soaks then more than the 1h, decocting at least 2 times boils more than 30 min at every turn, collecting decoction, and normal pressure vacuum filtration and concentrated is settled to the 100mL Chinese medicine extraction liquid.
The present invention compared with present technology, have that the medicine source is abundant, residual hazard is lower or do not have residual hazard, side effect little, be difficult for producing chemical sproof, can regulate body's immunity simultaneously, suppress virus replication, improve the advantage of clinical symptoms.
The specific embodiment:
The reality example is described further the present invention:
The present invention is by Flos Lonicerae 38-46 weight portions, Radix Paeoniae Rubra 34-42 weight portions, and Rhizoma Dryopteris Crassirhizomatis 18-22 weight portions constitute, and the consumption of each component is as shown in table 1 below.
Table 1:
| ? | Embodiment 1 | Embodiment 2 | Embodiment 3 |
| Flos Lonicerae | 38 | 44 | 46 |
| Radix Paeoniae Rubra | 42 | 34 | 36 |
| Rhizoma Dryopteris Crassirhizomatis | 20 | 22 | 18 |
Here, for easy to use, the formation of 100g each component of the present invention is crushed at least 20 orders, soaks then more than the 1h, decocting at least 2 times boils more than 30 min at every turn, collecting decoction, and normal pressure vacuum filtration and concentrated is settled to the 100mL Chinese medicine extraction liquid.
Adopt Chinese medicine extraction liquid of the present invention to carry out following effect experiment.
Experimental technique among the following embodiment like no specified otherwise, is conventional method.
Used experiment material is following among the following embodiment:
(1) experimental animal
9 ~ 11 age in days SPF (specific pathogen free) Embryo Gallus domesticus are available from the agricultural fowl egg company limited of the big China in Guangdong; SPF level 15g ± 2g BALB/c mouse is available from Guangdong Medical Lab Animal Center.
(2) solution or reagent preparation
1.PBS preparation: take by weighing NaCl 8.0g, Na
2HPO
43.63g, KCl 0.2g KH
2PO
40.24g be dissolved in an amount of ultra-pure water, adjust pH to 7.4 is settled to 1000mL; The packing of 100ml/ bottle, 15 pounds of autoclaving 30min, 4 ℃ of preservations are subsequent use.
2. the preparation of 1% chicken erythrocyte suspension: earlier draw 3.8% liquor sodii citratis (its consumption be required blood volume 1/5),, put in the sterilization centrifuge tube from chicken wing vein haemospasia to required blood volume with sterilizing syringe; Adding sterilization PBS is anticoagulant 2 times, with the centrifugal 10min of 2000r/min, abandons supernatant; Add normal saline suspension blood cell again, the same method centrifugation is so with red blood cell washing three times; According to institute's expense, PBS is made into 1% suspension with sterilization, joins existing usefulness at present at last.
Effect experiment
1:
1. SIV (swine influenza virus) is to Embryo Gallus domesticus ID 50, median infective dose (EID
50
) mensuration
Viral liquid is made 10 times of doubling dilutions successively, be inoculated in 10 age in days chick embryo allantois intracavity, 4 repetitions are done in 0.2ml/ piece of each dilution factor inoculation, establish normal Embryo Gallus domesticus contrast simultaneously.Put hatching 72h in 37 ℃ of calorstats, discard dead embryo in the 24h, dead embryo and the 72h allantoic fluid of embryo of living behind the results 24h carries out the tire mensuration of (HA is the hemagglutinin of virus, and it is a kind of index of general indirect reaction viral level that HA tires) of HA.Press Reed-Muench Liang Shi method (test method of mensuration virus that a kind of medical science is general or 50% fatal dose of antibacterial) and calculate EID
50
. the present inventionChinese medicine extraction liquid
Mensuration to the maximum safe concentration of Embryo Gallus domesticus
Chinese medicine extraction liquid is made 2 times of doubling dilutions successively; Be diluted to 7 concentration such as original content, 1:2,1:4,1:8,1:16,1:32,1:64, be inoculated in 10 age in days chick embryo allantois intracavity then, 0.2ml/ piece of each dilution factor inoculation; Do 4 repetitions, establish the normal saline contrast simultaneously.Put 37 ℃ of calorstats and hatch 72 h, observe survival every day, discard dead embryo in the 24h.The Embryo Gallus domesticus all the highest drug level of survival is the initial concentration of formal test, and promptly Chinese medicine extraction liquid is to the maximum safe concentration of Embryo Gallus domesticus.
. the present inventionChinese medicine extraction liquid
The test of anti-swine flu virus in Embryo Gallus domesticus
Embryo Gallus domesticus is divided into three groups at random, adopts three kinds of dosing methods:
Mode one, add Chinese medicine earlier and add virus (Chinese medicine is to the blocking effect of SIV) again: earlier each Chinese medicine extraction liquid is inoculated in instar chicken embryo on the 10th; 0.2ml/ piece; Do 4 repetitions, put 37 ℃ of calorstats and hatch 2h, (virus need reach certain concentration or dosage ability infected person or cell to inoculate 100EID50 virus liquid then; 100EID50 is exactly a kind of method for expressing of viral dosage; The virus that refers to this dosage can make 50% Embryo Gallus domesticus infect) 0.2ml/ piece, 37 ℃ of constant temperature culture 72h measure the blood clotting (HA) of chick embryo allantoic liquid and tire.
Mode two, add virus earlier and add Chinese medicine (Chinese medicine is to the inhibitory action of SIV) again: earlier 100EID50 virus liquid is inoculated in instar chicken embryo on the 10th; 0.2ml/ piece; Do 4 repetitions, put 37 ℃ of calorstats and hatch 2h, inoculate each Chinese medicine extraction liquid 0.2ml/ piece then; 37 ℃ of constant temperature culture 72h measure the blood clotting (HA) of chick embryo allantoic liquid and tire.
Add together after mode three, Chinese medicine virus is mixed (Chinese medicine is to the direct killing action of SIV): earlier with each Chinese medicine extraction liquid with after the viral liquid of equivalent 100EID50 mixes, put 37 ℃ of 2h after, be inoculated in instar chicken embryo on the 10th, 0.2ml/ piece, do 4 repetitions.37 ℃ of constant temperature culture 72h measure the blood clotting (HA) of chick embryo allantoic liquid and tire.
Set up virus control and negative control simultaneously.
. date processing
Data are represented with
± S.E; (SPSS is a kind of generally acknowledged statistical analysis software with SPSS17.0 software; Be usually used in scientific research; Business survey statistics etc.; 17.0 be version number) statistical analysis, the result of acquisition table 2.
Table 2
Annotate: above data are for recording the HA meansigma methods; Compare with virus control, * representes
P﹤ 0.01, and difference is extremely remarkable.
Effect experiment
2:
1. the present inventionChinese medicine extraction liquid
Dead protective effect and life-saving effect to the swine influenza virus infecting mouse
(1) laboratory animal is divided into groups
BALB/c mouse is divided into normal control group, model control group, virazole group, 1 group of embodiment, 2 groups of embodiment, 3 groups of embodiment, 10 every group at random.
(2) laboratory animal administration
Each organizes mice all with gastric infusion, and 2 times/d, 0.2 ml/ time.Chinese medicine is respectively organized in infecting preceding 1 d and is begun administration, continuous 5 d.Simultaneously, normal control group, model control group give the equivalent distilled water
(3) laboratory animal counteracting toxic substances
With mice with etherization after, except that the normal control group, each is organized collunarium and inoculates 10 LD50 influenza virus, 50 μ l, the normal control winding kind 50 μ l PBS that sterilizes.
(4) experimental observation
Day by day observe the mouse invasion situation, record death toll, time-to-live, calculate mortality rate=(respectively organizing death toll/each group sum * 100%); Dead protective rate=(model control group mortality rate-administration group mortality rate)/model control group mortality rate * 100%]; Life-saving rate=(administration group mean survival time-model control group mean survival time)/model control group mean survival time * 100%.Its result is as shown in table 3:
Table 3
| Test is divided into groups | Mortality rate (%) | Dead protective rate (%) | Mean survival time (d) | Life-saving rate (%) |
| 1 group of embodiment | 60 | 40 | 8.4 | 100 |
| 2 groups of embodiment | 60 | 40 | 8.5 | 100 |
| 3 groups of embodiment | 60 | 40 | 8.3 | 100 |
| The virazole group | 80 | 20 | 6.5 | 75.7 |
| Model control group | 100 | 0 | 3.7 | 0 |
| The normal control group | 0 | 100 | ﹥14 | 100 |
2. the present inventionChinese medicine extraction liquid
Influence to swine influenza virus infecting mouse pneumonia
(1) laboratory animal grouping, administration, modeling are with 1 (1) (2) (3)
(2) infect back the 5th day (more than the fasting 8h) and weigh, pluck eyeball sacrificed by exsanguination mice, the aseptic lungs of winning inhale after removing surperficial unnecessary liquid with the PBS flushing and with aseptic filter paper that the weighing lung is heavy respectively.
It is following that lung index and lung index suppress the percentage rate computing formula:
Lung index=lungs weight (g)/mice weight (g) * 100
The lung index suppresses percentage rate=(matched group lung index mean-experimental group lung index mean)/matched group number * 100%
(3) statistical analysis: analyze with the SPSS17.0 software statistics, the result is as shown in table 4.
Table 4
| Test is divided into groups | The lung index | The lung index suppresses percentage rate (%) |
| 1 group of embodiment | 1.93±0.25 * | 31.10 |
| 2 groups of embodiment | 1.91±0.24 * | 31.79 |
| 3 groups of embodiment | 1.94±0.25 * | 31.00 |
| The virazole group | 1.95±0.22 * | 30.35 |
| Model control group | 2.80±0.10 | ? |
| The normal control group | 0.77±0.07 * | 72.5 |
Annotate: above data are compared with model control group, and * representes
P﹤ 0.01, and difference is extremely remarkable.
. the present inventionChinese medicine extraction liquid
Influence to swine influenza virus infecting mouse cytokine
(1) laboratory animal grouping, administration, modeling are with 1 (1) (2) (3)
(2) preparation of serum: infected the back the 5th day, the eyeball blood sampling places the sterilization centrifuge tube, room temperature blood natural coagulation 2 ~ 3 hours, centrifugal about 20 minutes (2000-3000 rev/min).The careful supernatant of collecting as deposition occurring, is answered recentrifuge in the preservation process.
(3) adopt ELISA test kit (ELISA, Chinese are elisa, are a kind of detection methods of routine, all general should the abbreviation in the technical literature data) to detect:
1. the dilution of standard substance and application of sample: encapsulate at the enzyme mark and to establish 10 holes, standard substance hole on the plate, in first, second hole, add standard substance 100 μ l respectively, in first, second hole, add standard substance diluent 50 μ l then, mixing; From first hole, second hole, respectively get 100 μ l then and be added to the 3rd hole and the 4th hole respectively, add standard substance diluent 50 μ l, mixing again in the 3rd, the 4th hole respectively; In the 3rd hole and the 4th hole, respectively get 50 μ l earlier then and discard, respectively get 50 μ l again and be added to respectively in the 5th, the 6th hole, in the 5th, the 6th hole, add standard substance diluent 50ul, mixing more respectively; Get respectively from the 5th, the 6th hole behind the mixing that 50 μ l are added to the 7th respectively, in the octal; Again the 7th, add standard substance diluent 50 μ l respectively in the octal; Behind the mixing from the 7th, get 50 μ l respectively the octal and be added in the 9th, the tenth hole; Add standard substance diluent 50 μ l again in the 90 hole respectively, from the 90 hole, respectively get 50 μ l behind the mixing and discard.(each hole application of sample amount of dilution back all is 50 μ l, and concentration is respectively 2400 pg/mL, 1600 pg/mL, 800 pg/mL, 400 pg/mL, 200 pg/mL).
2. application of sample: establish blank well (the blank hole does not add sample and enzyme marking reagent, and all the other each step operations are identical), testing sample hole respectively.Encapsulate at enzyme mark and to add sample diluent 40 μ l on the plate in the testing sample hole earlier, and then add testing sample 10 μ l (the final dilution factor of sample is 5 times).Application of sample is added on bottom, ELISA Plate hole with sample, does not touch hole wall as far as possible, rocks mixing gently.
3. incubation: with rearmounted 37 ℃ of incubations of shrouding film shrouding 30 minutes.
4. dosing: doubly the dilution back is subsequent use with distilled water 30 (48T 20 times) for (48T 20 times) times concentrated cleaning solution with 30.
5. washing: carefully take the shrouding film off, discard liquid, dry, cleaning mixture is filled it up with in every hole, leaves standstill after 30 seconds to discard, and so repeats 5 times, claps and does.
6. enzyme-added: every hole adds enzyme marking reagent 50 μ l, except the blank well.
7. incubation: operation is with 3.
8. washing: operation is with 5.
9. colour developing: every hole adds developer A50 μ l earlier, adds developer B50 μ l again, the light shaking mixing, and 37 ℃ of lucifuges developed the color 15 minutes.
10. stop: every hole adds stop buffer 50 μ l, cessation reaction (this moment, blue upright commentaries on classics was yellow).
(4) statistical analysis: analyze with the SPSS17.0 software statistics, its result is as shown in table 5.
Table 5
| Test is divided into groups | IL-2（x±s，ng/ml） | IFN-γ（x±s，ng/ml） | TNF-α（x±s，ng/ml） |
| Embodiment 1 | 2.96±0.24 * | 1.63±0.10 * | 0.48±0.06 ** |
| Embodiment 2 | 2.93±0.23 ** | 1.61±0.09 ** | 0.47±0.05 ** |
| Embodiment 3 | 2.95±0.25 * | 1.64±0.09 * | 0.49±0.05 ** |
| Virazole | 2.51±0.18 * | 1.40±0.19 * | 0.51±0.05 ** |
| The model contrast | 1.91±0.16 | 1.07±0.18 | 0.69±0.09 |
| Normal control | 2.17±0.19 | 1.17±0.11 | 0.43±0.03 ** |
Annotate: above data are compared with model control group, and * representes
P﹤ 0.05, significant difference; * representes
P﹤ 0.01, and difference is extremely remarkable.
(IL-2, interleukin II; IFN-γ: interferon gamma; TNF-α: necrosin & swells and ache; These three kinds of materials all are that the reaction body receives the resistance factor that produces behind the viral infection, can react the resistance of machine.X ± s representes that the method for expressing of data in the form is average ± standard error; What ng/ml represented is unit, promptly contains how many nanograms in every milliliter.Can (x ± s ng/ml) changes into: (and unit: ng/ml) or directly deletion also can).
Claims (2)
1. the herbal mixture medicament of control swine influenza virus is characterized in that by Flos Lonicerae 38-46 weight portions, Radix Paeoniae Rubra 34-42 weight portions, and Rhizoma Dryopteris Crassirhizomatis 18-22 weight portions constitute.
2. the herbal mixture medicament of control swine influenza virus according to claim 1; It is characterized in that the formation of 100g each component of the present invention is crushed at least 20 orders, soak more than the 1h decocting at least 2 times then; Boil more than 30 min at every turn; Collecting decoction, normal pressure vacuum filtration and concentrated is settled to the 100mL Chinese medicine extraction liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101862336A CN102697873A (en) | 2012-06-07 | 2012-06-07 | Compound Chinese medicinal preparation for preventing and treating swine influenza viruses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101862336A CN102697873A (en) | 2012-06-07 | 2012-06-07 | Compound Chinese medicinal preparation for preventing and treating swine influenza viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102697873A true CN102697873A (en) | 2012-10-03 |
Family
ID=46891120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101862336A Pending CN102697873A (en) | 2012-06-07 | 2012-06-07 | Compound Chinese medicinal preparation for preventing and treating swine influenza viruses |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102697873A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655757A (en) * | 2013-12-12 | 2014-03-26 | 佛山科学技术学院 | Traditional Chinese medicine compound for effectively resisting swine influenza virus |
| CN105943820A (en) * | 2016-06-21 | 2016-09-21 | 佛山科学技术学院 | Traditional Chinese medicine compound for resisting swine influenza and porcine reproductive and respiratory syndrome and extraction method thereof |
| CN107334867A (en) * | 2017-06-12 | 2017-11-10 | 河南中盛动物药业有限公司 | A kind of animal KANGKAN KELI and preparation method thereof |
| CN108576427A (en) * | 2018-03-02 | 2018-09-28 | 安徽宏亮饲料科技有限公司 | A kind of additive and preparation method thereof preventing small swine flu |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1365769A (en) * | 2001-01-19 | 2002-08-28 | 杨孟君 | Nano medicine 'Kanggan' and its preparing process |
| CN1370549A (en) * | 2001-02-27 | 2002-09-25 | 中国中医研究院中药研究所 | Common cold treating Chinese medicine and its prepn |
| CN1473596A (en) * | 2003-05-10 | 2004-02-11 | 红 彭 | Anti-cold oral drip-pill and preparing process |
| CN1698663A (en) * | 2004-05-21 | 2005-11-23 | 江西本草天工科技有限责任公司 | Ring form effervescence dosage and preparation method thereof |
| CN2745572Y (en) * | 2004-05-21 | 2005-12-14 | 江西本草天工科技有限责任公司 | Ring shaped Chinese medicine effervescent form |
| CN1957994A (en) * | 2005-10-31 | 2007-05-09 | 天津市润拓生物技术有限公司 | Animal use compound medicament with effect for clearing away the heat-evil and expelling superficial evils, and preparation method |
| CN101152267A (en) * | 2006-09-28 | 2008-04-02 | 浙江大学宁波理工学院 | Method of preparing anticold grain based on ultrasound wave auxiliary extraction technology |
| WO2010064061A1 (en) * | 2008-03-20 | 2010-06-10 | Zhou James Liu | Pharmaceutical compositions and methods of sinonasal delivering the same |
| CN102038757A (en) * | 2010-10-12 | 2011-05-04 | 北京同仁堂科技发展股份有限公司 | Quality inspection and control system for medicinal compositions |
| TW201201823A (en) * | 2010-07-07 | 2012-01-16 | Beijing Health Bureau Inst Of Clinical Pharmacy | Chinese herbal medicine for treating influenza caused by A-type H1N1 viruses |
-
2012
- 2012-06-07 CN CN2012101862336A patent/CN102697873A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1365769A (en) * | 2001-01-19 | 2002-08-28 | 杨孟君 | Nano medicine 'Kanggan' and its preparing process |
| CN1370549A (en) * | 2001-02-27 | 2002-09-25 | 中国中医研究院中药研究所 | Common cold treating Chinese medicine and its prepn |
| CN1473596A (en) * | 2003-05-10 | 2004-02-11 | 红 彭 | Anti-cold oral drip-pill and preparing process |
| CN1698663A (en) * | 2004-05-21 | 2005-11-23 | 江西本草天工科技有限责任公司 | Ring form effervescence dosage and preparation method thereof |
| CN2745572Y (en) * | 2004-05-21 | 2005-12-14 | 江西本草天工科技有限责任公司 | Ring shaped Chinese medicine effervescent form |
| CN1957994A (en) * | 2005-10-31 | 2007-05-09 | 天津市润拓生物技术有限公司 | Animal use compound medicament with effect for clearing away the heat-evil and expelling superficial evils, and preparation method |
| CN101152267A (en) * | 2006-09-28 | 2008-04-02 | 浙江大学宁波理工学院 | Method of preparing anticold grain based on ultrasound wave auxiliary extraction technology |
| WO2010064061A1 (en) * | 2008-03-20 | 2010-06-10 | Zhou James Liu | Pharmaceutical compositions and methods of sinonasal delivering the same |
| TW201201823A (en) * | 2010-07-07 | 2012-01-16 | Beijing Health Bureau Inst Of Clinical Pharmacy | Chinese herbal medicine for treating influenza caused by A-type H1N1 viruses |
| CN102038757A (en) * | 2010-10-12 | 2011-05-04 | 北京同仁堂科技发展股份有限公司 | Quality inspection and control system for medicinal compositions |
Non-Patent Citations (2)
| Title |
|---|
| 刘冯欢等: "抗感颗粒抗甲型流感病毒的实验观察", 《中华医学杂志》, vol. 90, no. 26, 13 July 2010 (2010-07-13) * |
| 吴国娟等: "抗病毒中药在兽医临床的应用与作用机制", 《纪念《国务院关于加强民间兽医工作的指示》五十周年暨2006中国中兽医发展高层论坛报告集》, 1 October 2006 (2006-10-01) * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655757A (en) * | 2013-12-12 | 2014-03-26 | 佛山科学技术学院 | Traditional Chinese medicine compound for effectively resisting swine influenza virus |
| CN105943820A (en) * | 2016-06-21 | 2016-09-21 | 佛山科学技术学院 | Traditional Chinese medicine compound for resisting swine influenza and porcine reproductive and respiratory syndrome and extraction method thereof |
| CN107334867A (en) * | 2017-06-12 | 2017-11-10 | 河南中盛动物药业有限公司 | A kind of animal KANGKAN KELI and preparation method thereof |
| CN108576427A (en) * | 2018-03-02 | 2018-09-28 | 安徽宏亮饲料科技有限公司 | A kind of additive and preparation method thereof preventing small swine flu |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101023997A (en) | Anti-fowl-plague Chinese medicine and preparing method | |
| CN101485647A (en) | Use of patchouli alcohol in preparing medicament | |
| CN101862391B (en) | Application of Chinese medicinal composition in preparing medicament for treating human cases of bird flu | |
| CN100577179C (en) | Application of chitin, chitosan and their derivatives in preparing antivirotic | |
| CN102697873A (en) | Compound Chinese medicinal preparation for preventing and treating swine influenza viruses | |
| CN101129455B (en) | Sophora extractive and method of preparing the same and application of the same | |
| CN107236713A (en) | The one plant of type of coxsackie B group 5 virus and its purposes for preparing infectious animal model and kit | |
| CN103784538A (en) | Traditional Chinese medicinal compound drug for effectively preventing and treating swine influenza | |
| CN103638147A (en) | Traditional Chinese medicine compound for resisting swine influenza virus | |
| CN102716180A (en) | Right supporting and toxin eliminating oral liquid and preparation method of oral liquid | |
| CN101869595A (en) | Preparation method and quality detection method of liquorice and gall oral liquid | |
| CN102697906A (en) | Compound Chinese medicinal preparation for preventing and treating swine influenza viruses | |
| CN105943820A (en) | Traditional Chinese medicine compound for resisting swine influenza and porcine reproductive and respiratory syndrome and extraction method thereof | |
| CN103463182A (en) | Preparation method and application of dracocephalum heterophyllum benth fractionated extracts | |
| CN106038536A (en) | Application of columbianedin to medicine preparation | |
| CN103239518B (en) | Traditional Chinese medicine composition for treating avian influenza | |
| CN103655757A (en) | Traditional Chinese medicine compound for effectively resisting swine influenza virus | |
| CN105998041A (en) | Application of rosmarinic acid-4-O-beta-D-glucoside in preparing drug for preventing and treating flu | |
| CN103356812B (en) | A kind of Radix Wikstroemae granule | |
| CN106237050A (en) | A kind of Chinese medicine compound of effective preventing and treating H1N1 and H3N2 swine flue and pig blue-ear disease and preparation method thereof | |
| CN105287539A (en) | Novel application of corydaline | |
| CN101991763B (en) | Application of traditional Chinese medicinal composition to preparing medicaments for resisting influenza virus | |
| CN111317752B (en) | Medicine for preventing or treating influenza virus infection and application | |
| CN104161902B (en) | A kind of new application of pharmaceutical composition and its preparation in Tamiflu is prepared | |
| CN103623042A (en) | Application of lung-heat-clearing stonecrop medicine composition to preparation of anti-influenza A virus medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121003 |